TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022

HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.

Jingjing Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.